Veradermics, Inc. (MANE)
97.88
-3.93
(-3.86%)
USD |
NYSE |
Aug 28, 16:00
98.06
+0.18
(+0.18%)
After-Hours: 20:00
Veradermics Cash from Operations (Quarterly) : -14.49M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -14.49M |
| March 31, 2026 | -21.17M |
| December 31, 2025 |
| Date | Value |
|---|---|
| June 30, 2025 | -15.64M |
| March 31, 2025 | -13.32M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Eli Lilly & Co. | 10.69B |
| EyePoint, Inc. | -62.35M |
| Elanco Animal Health, Inc. | 277.00M |
| Tarsus Pharmaceuticals, Inc. | 61.22M |
| Amylyx Pharmaceuticals, Inc. | -31.42M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -277.29M |
| Cash from Financing (Quarterly) | 442.70M |
| Free Cash Flow Per Share (Quarterly) | -0.3473 |
| Free Cash Flow to Equity (Quarterly) | -14.94M |
| Free Cash Flow to Firm (Quarterly) | -14.51M |